LENZ Projected Dividend Yield

Lenz Therapeutics Inc New ( NASDAQ : LENZ )

Graphite Bio develops therapies to cure a range of serious and life-threatening diseases. Co.'s gene editing platform is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Co.'s product candidate nulabeglogene autogedtemcel is designed to correct the genetic mutation responsible for sickle cell disease. Co.'s gene replacement approach is designed to allow it to replace dysfunctional genes with a normal copy of an entire gene at its normal location in the chromosome. Co. has two gene replacement programs, one for beta-thalassemia and another for X-linked severe combined immunodeficiency syndrome.

20 YEAR PERFORMANCE RESULTS